arrow
M

Matthias Thielmann

royal brompton & harefield nhs foundation trust
H指数:56
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery

一项多中心随机、双盲、安慰剂对照的2期临床试验,旨在评估心外手术后有肾损伤风险患者使用ilofotase alfa的安全性和有效性

2026-09-210
OA
From Equipoise to Evidence: Pre-Trial Setup of the European Uncomplicated Type B Aortic Repair Clinical Trial

从均衡到证据:欧洲非复杂型B型主动脉修复临床试验的预试验设置

2026-01-010
PRE
Early CABG with intraoperative hemoadsorption in patients on ticagrelor: Real-world data from the international Safe and Timely Antithrombotic Removal (STAR) registry

Storey, R.F.; Hassan, K.; Meyer, A.L.; Eberle, T.; deNeve, N.; Thielmann, M.; Bernardi, M.H.; Marczin, N.; Guenther, U.; Panholzer, B.; 等. 接受替卡格雷治疗患者的早期CABG联合术中血液吸附:来自国际安全及时抗凝剂去除(STAR)注册研究真实世界数据. 心血管血管重建医学. 2026, 82, 50–56. [Google Scholar] [CrossRef]

2026-01-012
OAAI
Hemoadsorption therapy in severe rhabdomyolysis: a report from the international, prospective COSMOS (CytOSorb® TreatMent of Critically ill PatientS) registry
2025-12-310
PRE
The international, prospective CytOSorbR○ treatMent Of critically ill patientS (COSMOS) registry: Interim results from the first 150 patients

Ferrer, R.; Thielmann, M.; Kribben, A.; Unglaube, M.; Tyczynski, B.; Kreutz, J.; Baumann, A.; Guenther, U.; Henzler, D.; Kirschning, T.; 等. 国际前瞻性CytOSorb®治疗危重患者(COSMOS)登记研究:前150例患者的中期结果。J. Intensiv. Med. 2025. [Google Scholar] [CrossRef]

2025-10-012
OAAI
Periprocedural Myocardial Infarction After Coronary Artery Bypass Grafting: Current Clinical Practices and Future Perspectives

冠状动脉旁路移植术后围术期心肌梗死:当前临床实践与未来展望

2025-10-010
PRE
Repair Versus Replacement in Mitral Valve Papillary Muscle Rupture: A Multicenter Study

二尖瓣乳头肌断裂的修复与置换:一项多中心研究

2025-09-011
OA
High-sensitivity point-of-care measurement of cardiac troponin

高敏床旁测量心脏肌钙蛋白

2025-08-010
OA
Gender-based outcomes following surgical aortic valve replacement: a multicentre propensity score matching analysis
2025-07-010
PRE
Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function

缺血性心脏病和心力衰竭中的线粒体靶点及其更高效临床转化的潜力。欧洲心脏病学会(ESC)心脏细胞生物学工作组与ESC心肌功能工作组的科学声明

2025-05-040
OAAI
Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial

治疗性alpha-1-microglobulin RMC-035减少心脏手术后肾损伤的有效性和安全性: 一项多中心、随机、双盲、平行组、2a期试验

2024-10-010
OAAI
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM)

2024 ESC外周动脉和主动脉疾病管理指南: 由欧洲心脏病学会 (ESC) 外周动脉和主动脉疾病管理工作组制定,并得到欧洲心胸外科协会 (EACTS) 的认可,欧洲罕见多系统血管疾病参考网络 (VASCERN) 和欧洲血管医学学会 (ESVM)

2024-08-3020
OA
Hybrid coronary revascularization: position paper of the European Society of Cardiology Working Group on Cardiovascular Surgery and European Association of Percutaneous Cardiovascular Interventions
2024-08-143
PRE
Long-term survival after surgical treatment for post-infarction mechanical complications: results from the Caution study
2024-02-073
OAAI